The group is headquartered in Xiangfang Development Zone, Harbin. The production bases of subordinate pharmaceutical companies are located in wuchang city, tieli city and Fuling District, with a total area of 360,000 square meters. All have passed GMP certification, and the modern marketing network has its own system. There are offices in 27 provinces (cities) and autonomous regions in China, which can produce nearly 200 "quasi" Chinese patent medicine products in 10 dosage forms, forming the exclusive development and first production of Hugan tablets and Weikangling capsules.
Heart-brain series represented by capsules, children's series drugs represented by Xiaoer Feire Kechuan Oral Liquid, and sunflower series drugs represented by Shuang Hu Zhitongning Spray, the sunflower brand is as good as a promise, and the sunflower products sell well all over the country.
Heilongjiang sunflower pharmaceutical co., ltd, the core enterprise of the group, was restructured from the former state-owned Wuchang pharmaceutical factory on the verge of bankruptcy in April 1998. One of its leading products, Sunflower Liver Protection Tablets, won more than 30 domestic and foreign awards including two national quality silver awards (golden vacancies). Since 20001,it has become the first choice brand of drugs for treating hepatobiliary diseases in China, and its sales volume has been ranked first in the list of drugs for hepatobiliary diseases in China, and it has been recognized as "the best-selling well-known commodity in China in 20001year" by the Information Center of the National Bureau of Statistics. In July, 2002, Sunflower Hugan Tablet, Weikangling Capsule and Xiaoer Feire Kechuan Oral Liquid were rated as "Good Products with Reliable Quality Certified by National Authority" by China Quality Certification Standards Association. The enterprise has become a member enterprise directly under the All-China Federation of Industry and Commerce and a member unit in china association of traditional chinese medicine. It has been rated as a large-scale modern Chinese patent medicine manufacturing enterprise in China, a key high-tech enterprise in the National Torch Program, a national enterprise that respects contracts and keeps promises, an advanced private enterprise in employment and social security, and an advanced unit in political and ideological work of private enterprises in China, and has passed the national GMP and ISO900 1 certification. In July 2007, the sunflower trademark was recognized as a well-known trademark in China by the State Administration for Industry and Commerce.
In the nine years since the reform, under the leadership of Mr. Guan, the national model worker, chairman and president, and under the guidance of the value concept of "industry serving the country and contributing to society", Sunflower people have promoted enterprises to the domestic first-class and international advanced goals with advanced market awareness, development concept, advanced management mechanism and open talent concept, which has enabled Sunflower Pharmaceutical to achieve extraordinary and leap-forward development. From 1999 to 2002, the company has created a growth rate of 300% for four consecutive years. During the nine years of restructuring (up to the first half of 2007), the total tax paid was 550 million yuan, ranking first among private enterprises in Heilongjiang Province for three consecutive years and first among Chinese medicine manufacturing enterprises in Heilongjiang Province for five consecutive years. In 2006, the tax payment of enterprises ranked 35th among the top 100 taxpayers in the national pharmaceutical manufacturing industry.
At present, the company has 42 provincial offices in 30 provinces across the country, controlling more than 200 first-class merchants; More than 2,000 secondary dealers and more than 80,000 terminals. Over the past nine years, the company has created more than 3,000 jobs and arranged more than 2,600 laid-off workers and graduates. In 2006, the company's annual per capita income was 65,438+0.96 times the local average. Over the past nine years, the company has trained more than 65,438+000 millionaires and donated more than 4 million yuan to social welfare undertakings. Enterprises actively participate in various social welfare undertakings and strive to assume greater social responsibilities.
At present, the new drugs Shuangshen Yigan Dropping Pills and Hugan Dropping Pills, which the company invested more than 654.38+million yuan, have completed the second phase of clinical practice and will soon enter the third phase of clinical practice, which will become a stronger development momentum of the company after listing. This year, the company invested 1 100 million yuan to build a Chinese medicine extraction center, sewage treatment station, underground alcohol depot and other related supporting projects in Wuchang with an annual extraction capacity of 6,000 t, which started on June 18 and is expected to be put into use in 2008, which will provide strong support for sunflower pharmaceutical group to realize intensive management and greater development. Our goal is to upgrade to1500 million in about three years on the basis of the existing 800 million sales platform.
Sunflowers are more beautiful and upright after nine years of wind and rain. Under the banner of "industry serving the country and contributing to society", 3,000 sunflower children are striving to make greater contributions to the revitalization of traditional Chinese medicine and the revitalization of the old industrial base in Northeast China!